MDNA
Price:
$0.157
Market Cap:
$146.19M
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a ...[Read more]
Industry
Biotechnology
IPO Date
2017-11-13
Stock Exchange
NASDAQ
Ticker
MDNA
According to Medicenna Therapeutics Corp.’s latest financial reports and current stock price. The company's current PE Ratio is -1.74. This represents a change of -69.31% compared to the average of -5.67 of the last 4 quarters.
The mean historical PE Ratio of Medicenna Therapeutics Corp. over the last ten years is -10.10. The current -1.74 PE Ratio has changed 1.62% with respect to the historical average. Over the past ten years (40 quarters), MDNA's PE Ratio was at its highest in in the December 2016 quarter at -0.36. The PE Ratio was at its lowest in in the June 2015 quarter at -48.99.
Average
-10.10
Median
-6.65
Minimum
-50.53
Maximum
36.82
Discovering the peaks and valleys of Medicenna Therapeutics Corp. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 233.47%
Maximum Annual PE Ratio = 36.82
Minimum Annual Increase = -1031.01%
Minimum Annual PE Ratio = -50.53
Year | PE Ratio | Change |
---|---|---|
2024 | -4.95 | -113.44% |
2023 | 36.82 | -1031.01% |
2022 | -3.96 | -73.22% |
2021 | -14.77 | 6.86% |
2020 | -13.82 | 233.47% |
2019 | -4.14 | -37.76% |
2018 | -6.66 | 0.15% |
2017 | -6.65 | -79.46% |
2016 | -32.37 | -35.94% |
2015 | -50.53 | -8.13% |
The current PE Ratio of Medicenna Therapeutics Corp. (MDNA) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
9.31
5-year avg
-0.13
10-year avg
-10.10
Medicenna Therapeutics Corp.’s PE Ratio is less than Achilles Therapeutics plc (-0.69), greater than Checkpoint Therapeutics, Inc. (-3.38), less than Cue Biopharma, Inc. (-1.16), less than Pieris Pharmaceuticals, Inc. (-1.13), less than Eliem Therapeutics, Inc. (0), less than Ikena Oncology, Inc. (-1.24), greater than Ovid Therapeutics Inc. (-2.11), less than Connect Biopharma Holdings Limited (7.21), greater than Edgewise Therapeutics, Inc. (-22.36), greater than Protara Therapeutics, Inc. (-2.75), less than Vaccinex, Inc. (-0.13), less than Monopar Therapeutics Inc. (-0.59), greater than Miromatrix Medical Inc. (-7.13), less than Surrozen, Inc. (-0.89), less than Passage Bio, Inc. (-0.58), less than Magenta Therapeutics, Inc. (-0.15), less than TRACON Pharmaceuticals, Inc. (0.02), less than Invivyd, Inc. (-0.27), greater than Aptevo Therapeutics Inc. (-2.15), less than Werewolf Therapeutics, Inc. (-1.08), less than Oncorus, Inc. (-0.04), less than SAB Biotherapeutics, Inc. (-0.83), less than Akari Therapeutics, Plc (-0.61),
Company | PE Ratio | Market cap |
---|---|---|
-0.69 | $46.85M | |
-3.38 | $175.20M | |
-1.16 | $63.98M | |
-1.13 | $17.96M | |
0 | $342.68M | |
-1.24 | $73.83M | |
-2.11 | $68.62M | |
7.21 | $55.03M | |
-22.36 | $2.80B | |
-2.75 | $177.43M | |
-0.13 | $3.16M | |
-0.59 | $116.38M | |
-7.13 | $92.95M | |
-0.89 | $39.78M | |
-0.58 | $40.24M | |
-0.15 | $42.44M | |
0.02 | $109.72K | |
-0.27 | $60.99M | |
-2.15 | $2.42M | |
-1.08 | $68.63M | |
-0.04 | $0 | |
-0.83 | $37.84M | |
-0.61 | $11.90M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Medicenna Therapeutics Corp. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Medicenna Therapeutics Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Medicenna Therapeutics Corp.'s PE Ratio?
How is the PE Ratio calculated for Medicenna Therapeutics Corp. (MDNA)?
What is the highest PE Ratio for Medicenna Therapeutics Corp. (MDNA)?
What is the 3-year average PE Ratio for Medicenna Therapeutics Corp. (MDNA)?
What is the 5-year average PE Ratio for Medicenna Therapeutics Corp. (MDNA)?
How does the current PE Ratio for Medicenna Therapeutics Corp. (MDNA) compare to its historical average?